Day One Bio Files 8-K: Asset Disposition, Control Changes
Ticker: DAWN · Form: 8-K · Filed: Apr 23, 2026 · CIK: 0001845337
Sentiment: neutral
Topics: asset-disposition, change-of-control, corporate-action
TL;DR
Day One Bio selling assets, control might be changing. Big moves happening.
AI Summary
Day One Biopharmaceuticals, Inc. filed an 8-K on April 23, 2026, reporting several material events. These include the termination of a material definitive agreement, completion of an acquisition or disposition of assets, and potential changes in control of the registrant. The filing also notes potential modifications to security holder rights and changes in directors or officers.
Why It Matters
This 8-K filing indicates significant corporate actions at Day One Biopharmaceuticals, including asset disposals and potential shifts in control, which could impact the company's strategic direction and shareholder value.
Risk Assessment
Risk Level: medium — The filing details significant corporate events like asset disposition and potential changes in control, which inherently carry higher risk and uncertainty.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Filer of the 8-K report
- 0001845337 (company) — CIK number for Day One Biopharmaceuticals, Inc.
- 2026-04-23 (date) — Filing date of the 8-K
- 2026-04-22 (date) — Period of report for the 8-K
FAQ
What specific material definitive agreement was terminated by Day One Biopharmaceuticals, Inc.?
The filing indicates the termination of a material definitive agreement under Item 1.02, but the specific details of the agreement are not provided in this summary.
What acquisition or disposition of assets was completed?
Item 2.01 of the 8-K reports the completion of an acquisition or disposition of assets, but the nature and details of these assets are not specified in the provided text.
Are there any changes in the control of Day One Biopharmaceuticals, Inc.?
Item 5.01 addresses changes in control of the registrant, suggesting this is a reported event in the filing, though specifics are not detailed here.
Were there any departures or appointments of directors or officers?
Item 5.02 of the 8-K filing covers the departure of directors or certain officers, election of directors, and appointment of certain officers, indicating such events occurred.
What is the mailing and business address for Day One Biopharmaceuticals, Inc.?
The mailing and business address for Day One Biopharmaceuticals, Inc. is 1800 SIERRA POINT PARKWAY, SUITE 200 BRISBANE CA 94005.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2026 regarding Day One Biopharmaceuticals, Inc. (DAWN).